Share this post on:

The resistant cells experienced tiny amounts of experienced mesothelin, but the precursor was not detected, probably because of to its minimal abundanceHIF-2α-IN-1 (Fig. 2B). Excessive shedding of mesothelin in KLM-one-R could account for minimal mesothelin surface area levels. Making use of the Meso Scale Assay, we found that drop mesothelin mesothelin expression and RG7787 uptake is lowered in KLM-1-R. A: Floor mesothelin ranges are 5-fold decrease in resistant KLM-one (KLM-one-R) in contrast to KLM-one. Mesothelin expression of KLM-one, KLM-1-R and mesothelin-damaging A431 cells (negative control) were evaluated utilizing movement cytometry. Crammed histograms are secondary antibody controls. B: Whole mesothelin protein level is reduced in KLM-1-R. Precursor (72 kDa) and cleaved experienced mesothelin (37 kDa) had been current in KLM-one. In KLM-1-R, the cleaved portion was detected at low amounts. Protein stages ended up probed in untreated KLM-one and KLM-one-R mobile lysate by Western blot. -actin acts as loading handle. C: At each time stage, cellular uptake of RG7787-Alexa647 in KLM-one is drastically increased than in KLM-one-R, and significantly reduce than in KLM-1-R-Msln (transfected with mesothelin). Uptake was evaluated at 30, seventy five and a hundred and fifty min. Average geomean fluorescence intensities transformed into volume of RG7787 molecules was 4.8 .03-fold reduced in the media of KLM-one-R (forty.7 five.3 pg/one zero five cells) when compared to KLM-one (149. 23.four pg/a hundred and five cells). In medium without having cells (negative handle), no mesothelin was detected. These knowledge are regular with the difference in surface ranges and point out that the reduced mesothelin on KLM-1-R is not due to elevated shedding. To decide if diminished mesothelin was because of to less mRNA, we carried out RT-PCR and located that mesothelin RNA was seven.3 4.three-fold reduce in KLM-1-R (CT = 24.one .09) in contrast to KLM-one (CT = 21.54 .73). To evaluate whether the remaining mesothelin on the KLM-one-R area could bind and internalize anti-mesothelin RITs, we evaluated the mobile internalization of RG7787-Alexa647. Uptake in KLM-one-R enhanced in excess of time, but was significantly lower than KLM-1 at each time level (four- to five-fold, p < 0.01). After 150 min incubation, e.g., KLM-1 internalized about 40 x 103 RG7787 molecules, compared to only 8 x 103 in KLM-1-R (Fig. 2C). These data demonstrate that KLM-1-R cells have a partial down-regulation in mesothelin and therefore internalize significantly less RG7787, providing a potential explanation for the observed resistance.Mesothelin expression can be silenced by DNA methylation of CpG sites in its promoter region [347]. AZA, a DNA methyltransferase inhibitor, can reverse such hypermethylation. We gave cells 500 nM AZA daily for 3 weeks, and found that mesothelin expression was increased in KLM-1-R (KLM-1-R-AZA) by about 3-fold, up to 34 x 103 sites per cell, which is still less than the 60 x 103 sites per cell in KLM-1 (Fig. 3A). AZA improved the sensitivity to RG7787 in KLM-1 and KLM-1-R, although the latter remained highly resistant after a 72 hr incubation (IC50 = 722.4 232.6 ng/ml) (Fig. 3B). These data link mesothelin down-regulation to hypermethylation.To confirm that the mesothelin gene is indeed subject to hypermethylation in KLM-1-R, we performed an exploratory analysis of the methylation status of seven CpGs in the mesothelin promoter region (chr16:808890-808742, S3 Fig.) using bisulfite sequencing. This 147-bp site region was selected based on the primers available at EpigenDx. Results demonstrated that these CpGs had a significantly higher methylation in KLM-1-R (59 3.6%) compared to KLM-1 (41 4.8%) (p < 0.05) (Fig. 3C). Treatment with AZA brought the methylation levels in KLM-1-R back to those of KLM-1 (p> .05). These information further support that mesothelin downregulation in KLM-1-R is associated with hypermethylation of the mesothelin gene.To restore mesothelin expression in KLM-1-R, we launched complete-duration mesothelin cDNA (KLM-1-R-Msln). Floor mesothelin expression of KLM-one-R-Msln was 22.6 5.three-fold higher than that of KLM-one-R, and exceeded the original expression in KLM-one by five.3 one.3-fold, resulting in about 300 x 103 sites for each cell (Fig. 3D). As a consequence, the uptake of RG7787-Alexa647 in KLM-1-R-Msln at each and every time stage was substantially higher than in KLM-1 (5- to 10-fold, p < 0.05) and KLM-1-R (24- to 46-fold, p < 0.001) (Fig. 2C). After a 72 hr incubation, RG7787 had a similar IC50 in KLM-1-R-Msln (4.49 1.11 ng/ml) as in KLM-1 (4.41 0.38 ng/ml) (p = 0.80). However, KLM-1-R-Msln was more sensitive than KLM-1 at higher RG7787 concentrations, with cell viability decreasing to zero at 100 ng/ml (Fig. 3E). Introduction of mesothelin downregulation is associated with CpG hypermethylation and mesothelin transfection restores sensitivity to of KLM-1-R to RG7787. A: AZA leads to a 2.8-fold increase of mesothelin surface expression in resistant KLM-1 (KLM-1-R). Flow cytometry histogram of KLM-1, KLM-1-R, and KLM-1-R-AZA. Filled histograms represent secondary antibody controls. B: Three weeks of incubation with AZA, a DNA methyltransferase inhibitor, increases sensitivity to RG7787. KLM-1, KLM-1-R, and the AZA-treated cells (KLM-1-AZA and KLM-1-R-AZA) were treated for 72 hrs with RG7787. Growth inhibition was evaluated with an ATP cell viability assay. Dotted lines represent AZA-treated cells. C: CpGs in a region upstream of the mesothelin transcription start site are more methylated in KLM-1-R than in KLM-1. Three weeks of incubation with AZA decreases methylation in KLM-1-R cells. The analyzed region is located at chr16:808890-808742 and spans 147 bp and seven CpGs. D: Mesothelin transfection in KLM-1-R results in significant overexpression of mesothelin compared to KLM-1 (5-fold) and KLM-1-R (23-fold). Flow cytometry surface mesothelin levels in KLM-1, KLM-1-R and mesothelin-transfected resistant cells (KLM-1-R-Msln). E: Mesothelin overexpression in KLM-1-R restores sensitivity to RG7787. KLM-1 and KLM-1-R-Msln cells were incubated for 72 hrs with RG7787. Growth inhibition was evaluated with an ATP cell viability assay control pcDNA3.1(+) had no effect on mesothelin levels or resistance to RG7787 (data not shown). These data confirm that the resistance in KLM-1-R is linked to a decrease in mesothelin. In order to achieve a similar level of sensitivity to RG7787 seen in KLM-1, KLM-1-R requires significantly higher mesothelin levels than KLM-1. This finding hints that resistance could also be tied to inefficient trafficking of RG7787 to the cytosol, or that protein synthesis inhibition is affected in KLM-1-R.Protein synthesis inhibition is initiated after the toxin traffics from the cell surface to the cytosol and inactivates EF-2 by ADP-ribosylation. KLM-1 cells were incubated with RG7787 for 16 hrs, and KLM-1-R cells for 16 and 48 hrs, after which protein synthesis was examined by measuring [3H]leucine incorporation (Fig. 4A). After 16 hrs, RG7787 induced a dose-dependent decrease in protein synthesis in KLM-1, but not in KLM-1-R. After 48 hrs, KLM-1-R showed a small decrease in protein synthesis at the higher concentrations of RG7787, reminiscent of the growth inhibition observed with the ATP assay (Fig. 1A). LMB-2 caused protein synthesis protein synthesis inhibition and EF-2 ADP-ribosylation in KLM-1-R. A: Protein synthesis inhibition by RG7787 is limited in resistant KLM-1 (KLM1-R). KLM-1 was incubated for 16 hrs with RG7787, and KLM-1-R for 16 and 48 hrs with RG7787 and anti-CD25 LMB-2. RG7787 induces a dose-dependent protein synthesis inhibition in KLM-1-R, which is absent in KLM-1-R. After 48 hrs, RGG778 induces some decrease in protein synthesis in KLM-1-R, which is also the case with LMB-2. Protein synthesis inhibition was evaluated by measuring [3H]leucine incorporation. B: Diphthamide Biosynthesis Protein (DPH) genes expression is not down-regulated in KLM-1-R, compared to KLM-1. Expression levels were evaluated with real time RT-PCR, standardized for actin and presented relative to KLM-1 C: EF-2 ADP-ribosylation is functional in KLM-1-R. RIT-induced EF-2 ADP-ribosylation was evaluated by incubating cell lysate with ADP-ribosylation buffer, 6-Biotin-17-NAD and 10 ng of RG7787 for 0, 15, 30 and 60 min at 25. Samples were subjected to SDS/PAGE followed by Western blotting with streptavidin HRP conjugate to detect biotin ADP-ribosylated EF-2. The 0 min time point and the sample without RG7787 are negative controls. D: EF-2 protein levels are on average 2-fold higher in KLM-1-R compared to KLM-1. Western blot was done on cell lysate of KLM-1 and KLM-1-R. -actin acts as loading control. Protein levels were quantified and adjusted for -actin levels with Image J. K: KLM-1, R: KLM-1-R,--no RG7787, + with RG7787 inhibition above 100 ng/ml after 48 hrs, confirming that the protein synthesis inhibition in KLM-1-R at higher RG7787 concentrations is in part attributable to non-specific uptake. Next, we evaluated whether the dismal protein synthesis inhibition by RG7787 in KLM-1-R was due to a problem with EF-2 ADP ribosylation. The toxin inactivates EF-2 by ADP-ribosylation of the diphthamide residue on EF-2, which requires the activity of enzymes DPH1 and 7 [3]. We measured expression of these six diphthamide genes by RT-qPCR and found no meaningful decrease in KLM-1-R, compared to KLM-1 cells (Fig. 4B). To investigate the status of EF-2 in KLM-1-R, we examined EF-2 protein levels and the ability of RG7787 to ADP-ribosylate EF-2 in cell-free extracts at different times of RG7787 incubation. On average, EF-2 levels were 2-fold higher in KLM-1-R cells compared to KLM-1 cells (Fig. 4D). At each time point, the amount of EF-2 that was ADP-ribosylated by RG7787 was similar in KLM-1 and KLM-1-R (Fig. 4C). These data demonstrate that the dismal protein synthesis inhibition in KLM-1-R is not linked to downregulation of DPH enzymes or failure of the toxin to ADP-ribosylate EF-2. These data show that the anti-mesothelin RIT resistance is linked to events occurring upstream of protein synthesis inhibition, which is in agreement with the earlier findings that the resistant and KLM-1 cells were equally sensitive to the anti-CD71 HB21(Fv)-PE40.We carried out RNA deep sequencing on KLM-1 and KLM-1-R cells and analyzed the data set using Qlucore. Applying the software's algorithm for variance, we identified the top up- and down-regulated genes for KLM-1 versus KLM-1-R. The list of genes was separated in KLM1-R's up- (488 genes) and down- (501 genes) regulated genes, respectively (S2 Table). Similar to our earlier RT-PCR data, mesothelin (MSLN) was 9.08-fold down-regulated in KLM-1-R. To validate the dataset further, we checked for expression levels and fold-changes of common housekeeping genes and found them to be highly expressed (e.g. actin 0.5% of total counts) with no significant changes between sensitive and resistant cells (actin 1.117-fold, ribosomal protein L22 1.085-fold change). The RNA sequencing dataset was considered reliable as it confirmed the experimentally proven down-regulation of MSLN in KLM-1-R and displayed stability in housekeeping genes between the data sets.The two sets of up- and down-regulated genes of KLM-1-R were separately applied to the GSEA database supplied by the Broad Institute [38]. GSEA sets with high similarity to our dataset were picked and applied to the whole unfiltered KLM-1/KLM-1-R data set of 25671 genes. One of the GSEA sets, "missiaglia_regulated_by_methylation_dn", showed high similarity to our data. This GSEA set was originally generated by treating PDAC cell lines with AZA24446111 [39]. Of the 122 down-regulated genes in this GSEA, 97 (80%) were also down-regulated in the KLM-1-R cell population, whereas 20 genes (16%) were up-regulated and 5 genes (4%) were not overlapping (S4 Fig.). In accordance with above-described promoter methylation analysis of the MSLN gene, these data indicate a more general hypermethylated state in KLM-1-R.Table was generated by STRING using GO, KEGG, and Reactome databases, as indicated under dataset reference umber of genes in our data set that are also present in the respective data-set list or pathway list p-value represents the probability that 478 genes would show the distribution to match the same number of gene hits in the respective list. Datasets are ranked according to p-value. P < 0.001 is considered statistically significant.The gene lists generated by Qlucore were next analyzed with the online tool STRING [30]. This tool clusters proteins based on databases from genomic contexts, high throughput experiments and co-expression, and implements a Pubmed text search. The resulting protein network can then be analyzed by GO annotations or by Reactome and KEGG pathway comparisons to screen for significances in differentially expressed gene sets. Up- and down-regulated genes were again kept separated in this analysis. Looking at the up-regulated genes in KLM-1-R, the largest sets showed genes that are involved in translation, transport and stress responses (Table 1). In accordance with an increased protein production, genes for unfolded protein response, tRNA-synthesis as well as metabolic RNA processes were up-regulated. An increase in these datasets resulted in highly significant p-values (< 0.001) for the GO-BL (gene ontology, biological function), KEGG, and Reactome pathway analyses. The dataset for down-regulated genes of KLM-1-R generally showed less clear patterns and lower significance levels, with several of them not reaching the p < 0.001 threshold for statistical significance (Table 1), including the transport-related datasets. Overall, the deep sequencing analyses of KLM-1 and KLM-1-R show profound changes in the expression profile of many cellular processes that are supportive of our earlier experimental observations.To gain insight into resistance mechanisms to anti-mesothelin RITs, we isolated and characterized resistant cells from the PDAC cell line KLM-1. These KLM-1-R cells were highly resistant against cell death and protein synthesis inhibition by various anti-mesothelin RITs, including RG7787, a novel de-immunized RIT optimized for clinical use [19] but not against HB21(Fv)PE, an immunotoxin targeting the transferrin receptor. Previously reported mechanisms of resistance to the anti-CD22 Moxetumomab pasudotox RIT are directly linked to silencing or deletion of DPH genes, which prevents EF-2 ADP-ribosylation and subsequent protein synthesis inhibition [5].

Share this post on: